Mason Freeman - 06 Jan 2022 Form 3 Insider Report for CinCor Pharma, Inc.

Role
EVP Clinical Development
Signature
/s/ Cathy Rude, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Jan 2022
Net transactions value
$0
Form type
3
Filing time
06 Jan 2022, 19:49:50 UTC
Next filing
13 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CINC Stock Option (Right to Buy) 06 Jan 2022 Common Stock 30,178 $0.9200 Direct F1
holding CINC Stock Option (Right to Buy) 06 Jan 2022 Common Stock 145,296 $5.82 Direct F2
holding CINC Stock Option (Right to Buy) 06 Jan 2022 Common Stock 120,380 $7.62 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vested or shall vest in equal monthly installments over a three-year period measured from one month following July 10, 2019, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.
F2 One-fourth (1/4th) of the shares subject to the option vest on August 9, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
F3 One-fourth (1/4th) of the shares subject to the option vest on November 4, 2022, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney